Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hiromitsu Yokota"'
Autor:
Yumiko Satoh, Hironori Shimosaka, Mineo Kurokawa, Hiromitsu Yokota, Michiko Terashima, Akiko Masuda, Masahiro Jona, Yutaka Yatomi, Yasuhito Nannya
Publikováno v:
International journal of hematology. 101(6)
Publikováno v:
Rinsho byori. The Japanese journal of clinical pathology. 62(4)
The pathogenic chromosome translocations present in various hematological malignancies result in the formation of fusion genes, which are detected by a reverse transcription-polymerase chain reaction method. Furthermore, with this method, it is possi
Autor:
Mineo Kurokawa, Keiki Kumano, Naoko Watanabe-Okochi, Tomohiko Sato, Hiromitsu Yokota, Toshiyuki Ikeda, Akihide Yoshimi, Yumiko Satoh, Jiro Kitaura, Toshio Kitamura, Yutaka Yatomi, Koki Takahashi, Akihito Shinohara, Kazuki Taoka, Akiko Masuda, Takako Tsuruta
Publikováno v:
Scopus-Elsevier
Ecotropic viral integration site 1 (Evi1) is one of the master regulators in the development of acute myeloid leukemia (AML) and myelodysplastic syndrome. High expression of Evi1 is found in 10% of patients with AML and indicates a poor outcome. Seve
Publikováno v:
Rinsho byori. The Japanese journal of clinical pathology. 60(8)
Quantitative analysis of the leukemia fusion gene by real-time PCR is a sensitive method to monitor minimal residual disease; the data obtained are very useful to evaluate the disease stage and prognosis, contributing to the clinical practice of hema
Publikováno v:
Rinsho byori. The Japanese journal of clinical pathology. 56(5)
The pathogenic chromosome translocations present in various hematological malignancies result in the formation of fusion genes, which are detected by a reverse transcription-polymerase chain reaction (RT PCR) method. Furthermore, with this method, it
Autor:
Mineo Kurokawa, Toru Motokura, Motoshi Ichikawa, Hiromitsu Yokota, Shigeru Chiba, Tsuyoshi Takahashi, Yutaka Yatomi, Kumi Oshima, Hiroyuki Sato, Akira Hangaishi, Sumimasa Nagai, Yoshinobu Kanda, Koji Izutsu
Publikováno v:
Experimental hematology. 35(11)
Objective Systemic mastocytosis with associated clonal hematological non–mast cell lineage disease (SM-AHNMD) is a distinct entity that was defined by World Health Organization. Systemic mastocytosis with acute myeloid leukemia (AML) is frequently